Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial Officer

   Trevena Appoints Roberto Cuca as Senior Vice President & Chief Financial

PR Newswire

KING OF PRUSSIA, Pa., Sept. 17, 2013

KING OF PRUSSIA, Pa., Sept. 17, 2013 /PRNewswire/ --Trevena, Inc., (Trevena)
a clinical stage pharmaceutical company and a leader in the discovery and
development of G-protein coupled receptor (GPCR) biased ligands, today
announced the appointment of Roberto Cuca as senior vice president and chief
financial officer.

"We are delighted to have Roberto join Trevena at this pivotal juncture in the
company's development," said Maxine Gowen, Ph.D., president and chief
executive officer of Trevena. "Roberto's diverse experience in effectively
transitioning both private and public healthcare companies through phases of
rapid growth will be invaluable in assisting Trevena through its corporate and
strategic evolution."

Mr. Cuca brings to Trevena nearly 20 years of experience in the pharmaceutical
and biotechnology industries. Most recently, he served as Treasurer and Senior
Vice President, Finance at Endo Health Solutions Inc., a specialty healthcare
company. Before that, he was Director, Corporate and Business Development, at
moksha8 Pharmaceuticals, Inc., a pharmaceutical company focused on emerging
markets. Mr. Cuca also worked at JPMorgan Chase & Co. as an equity analyst
covering U.S. pharmaceutical companies. He received an M.B.A. from the Wharton
School of The University of Pennsylvania, a J.D. from Cornell Law School, an
A.B. from Princeton University and he is a CFA charterholder.

"I am excited to join Trevena and work with its exceptional team at a time of
such great promise," said Mr. Cuca. "The company has made significant progress
in advancing its compounds into the clinic, collaborating with world-class
global pharmaceutical companies and successfully securing financing to support
the development of its clinical programs. I look forward to helping the
company progress towards its next phase of development."

About Biased Ligands
GPCRs are the targets of at least one-third of modern medicinal products, and
remain the predominant class of targets under clinical evaluation. However,
traditional ligands either turn on, or turn off, all of the signaling pathways
engaged by a particular receptor, which can result in efficacy limitations or
undesirable adverse effects. Trevena's expertise lies in engineering "biased
ligands" that activate only the beneficial signaling pathways downstream of a
GPCR to unlock new biology and avoid drug adverse effects.

About Trevena
Trevena, Inc. is a privately held, clinical stage pharmaceutical company that
has built a pipeline of biased GPCR ligands to address unmet medical needs in
cardiovascular, pain and other CNS conditions. The company's drug discovery
technology is based on extensive research from the laboratory of Nobel Prize
winning scientist Robert J. Lefkowitz, M.D. of Duke University Medical Center.
The lead drug in Trevena's portfolio, TRV027, is a first-in-class agent in
Phase 2 testing for the treatment of acute heart failure. TRV027 is being
developed by Trevena under a recently announced collaborative licensing option
agreement with Forest Laboratories Inc. (NYSE: FRX). Trevena's pipeline also
includes a clinical stage mu-opioid biased ligand, TRV130, in development for
post-operative pain, a pre-clinical program for chronic pain, and
discovery-stage programs for pain and Parkinson's disease. Trevena is based in
King of Prussia, Pennsylvania and is backed by Alta Partners, Healthcare
Ventures, NEA, Polaris, Forest Holdings and Yasuda Enterprise Development
Company. For more information about the company, please visit

For more information, please contact:
Ros Deegan, VP Business Development, Trevena Inc., 610-354-8840 x225
Kimberly Minarovich, Christensen, 917-533-3268 (Media)

SOURCE Trevena, Inc.

Press spacebar to pause and continue. Press esc to stop.